Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action

See allHide authors and affiliations

Science Translational Medicine  26 Oct 2016:
Vol. 8, Issue 362, pp. 362ps17
DOI: 10.1126/scitranslmed.aaf9246

You are currently viewing the abstract.

View Full Text


Poly(ADP-ribose) polymerase (PARP) inhibitors are the first DNA damage response targeted agents approved for cancer therapy. Here, we focus on their molecular mechanism of action by PARP “trapping” and what this means for both clinical monotherapy and combination with chemotherapeutic agents.

View Full Text